Week
53:
- Wednesday December 29th saw publication of 2,284 new PCT applications by
WIPO, the output for “Week 53” of 2004. This brings the total
for the year to 114,739, an average of 2165 per week...
- The PDJ from the UKPTO is a little light in the SPC department this week,
with no filings, grants or expiries reported...
- An application from inventors named Holmes and Watson based at GSK’s
Greenford site heightened the Christmas merriment in the Current Patents Gazette
office this week. Entitled “Inhibitors of matrix metalloproteinase”,...
- A0s from PDJ6032, Nov 24-30th - due for publication early June 2006...
|
Week
52:
- This weeks PDJ announced that SPC/GB03/038 for enfuvirtide had been granted
to Chiron on their EP181150 patent...
- In a further SPC related development this week, the appeal by Yissum Research
and Development Co against the Patent Office’s rejection of an SPC application
(SPC/GB02/023) has been stayed following the High Court’s referral to
the ECJ of two questions of interpretation of the SPC Regulation. The SPC
had been rejected on grounds that marketing authorisations...
- Also, following questions referred to the ECJ in another case, whether “combination
of active ingredients of a medicinal product” for the purposes of Article
1(b) of the Regulation, meant that all components of the combination had to
be active ingredients with a therapeutic effect...
|
Week
51:
- The latest issue of sibprima, the IP newsletter from Società
Italiana Brevetti, includes a useful commentary on EP148605, the
Kirin-Amgen cases relating to erythropoietin (EPO) that was recently
revoked by the UK House of Lords. This decision, taken on the
grounds of lack of novelty...
- In our “A0” section each week we take an early look
at initial patent applications filed at the UK Patent Office.
It takes five or six weeks for these bibliographic details to
appear in the Patents and Designs Journal, so that at least a
further 16 months must elapse before publication of the specification
takes place, if indeed that stage is ever reached...
- The grant of a UK SPC protecting AstraZeneca’s treatment
for breast cancer, fulvestrant was formally announced in the PDJ
this week. Based upon EP138504 this SPC gives protection to fulvestrant
until 1st October 2009...
|
Week
50:
- Very many of the chemical and pharmaceutical companies represented in this
issue of our Gazette were also present as exhibitors at CPhI in Brussels earlier
in the week. CPhI, for those who have not yet come across it, is a global
industry forum now in its 15th year, the Convention on Pharmaceutical Ingredients.
More than 1400 exhibitors...
- Bayer Healthcare AG has filed on modified (anti)estrogens which originally
we thought must be adducts of known compounds, since the title refers to targeted
chemotherapy for tumors of hormone-dependent organs. However, after some research,
we infer that a herbicide chemist...
- This week’s PDJ contained a notice on the revocation of GB2235627
(which also has an SPC for a salmeterol xinafoate and fluticasone propionate
combination). The order of events recorded in the Patent Status Information
shows that the High Court ordered the patent revoked in April, but the revocation
was stayed whilst GSK...
- Also contained in the PDJ are details of the entry into force of the SPC
for imiquimod, extending the protection for 3M’s Riker Laboratories
to November 2009. Imiquimod, launched as Aldara in the US and Zartra in Europe,
is an orally and topically active immune response modifier...
|
Week
49:
- The UK Patents and Designs Journal (PDJ) this week includes notice of the
grant of Supplementary Protection Certificate SPC/GB99/015 in relation to
omeprazole sodium...
- The UK Comptroller has allowed amendments to correct errors in the EP837672
specification granted to Yeda in November 2003. The case is likely to read
on to the diabetes treatment DiaPep277...
- The November Japanese patent gazette contained details of the grants of
8 patent extensions, with all but 2 of these being for agrochemicals. The
two pharmaceutical references were both granted to Pfizer for azithromycin
hydrate...
- On Monday, November 29, 2004 the Court of Appeal for England and Wales ruled
that Glaxo’s patent for its SEROXAT paroxetine hydrochloride anhydrate
was valid but that Apotex did not infringe it. In Smithkline Beecham plc and
others...
|
Week
48:
- Two UK SPC applications have been published this week. The first
assigned to Genentech relates to efalizumab the company's humanized
anti-CD11a monoclonal antibody for the treatment of psoriasis...
- Official confirmation that two SPCs have now entered into force
was published in the PDJ this week. Both of these SPCs are assigned
to Serono...
- Pharmacia & Upjohn has this week published a PCT application
disclosing a combination of irinotecan and revimid for the treatment
of multiple myeloma...
- Also published this week is the first PCT application from
Chroma Therapeutics relating to the company's glyoxalase I inhibitor
project...
- Ranbaxy is set to challenge two of Pfizer's patents covering
atorvastatin in the U.S. District Court...
- UK initial ("A0") applications filed October 19th
- 26th 2004...
|
Week
47:
- Official notice of the expiry of a UK SPC protecting Tokyo Tanabe's
beractant formulation was published this week. The SPC was based
on GB2050832...
- Also published this week were two UK SPC applications, both
are assigned to Aventis and Imclone...
- A process application from Ranbaxy this week is directed to
the preparation of cell adhesion inhibitors originally described
in WO0042053. Compounds covered in the earlier case...
- is week also sees an interesting PCT application from Merck
Sharp & Dohme. It discloses a combination of MSD's own aprepitant
launched for the treatment of chemotherapy...
- GlaxoSmithKline has recently filed several dedications on three
of it patents relating to sumatriptan succinate (Imitrex)...
- It is announced in last week's UK Patents and Designs Journal
that EP668782 (Temple Univ & Thomas Jefferson Univ) has been
revoked...
- UK Initial ("A0") Applications filed October 12th
- 19th 2004...
|
Week 46:
- Lundbeck granted SPC protecting escitalopram...
- Novo Nordisk files an SPC application for Levemir...
- Official notice of the expiry of a UK SPC protecting the imaging agent
ioversol was also published this week...
- UK initial (“A0”) applications filed October 7th –
October 13th 2004...
|
Week 45:
- Patent Cooperation Treaty to enter into force in San Marino...
- UK SPC relating to bivalirudin filed and angiomax SPC granted...
- This week sees the publication of a flurry of patent applications from
all over the world relating to the detection, prevention and/or treatment of
Severe Acute Respiratory Syndrome (SARS) coronavirus infection...
- We are used to seeing applications claiming new uses of existing compounds
however, filings describing new actions are much rarer. This week sees the publication
of such an application from Eisai...
- Glaxo gives possible clues to glucocorticoids in inhaler application...
- UK initial (“A0”) applications filed September 30th –
October 6th 2004...
|
Week 44:
- European Commission debate proposal for "Regulation of Medicinal
Products for Paediatric Use"...
- Patent extensions and applications for extensions from Japan...
- Extensions from UK Patents and Designs Journal...
- UK Initial ("A0") Applications filed September 22nd - 29th
2004...
|
Week 43:
- SPC application filed for pregabalin...
- Official confirmation that the UK SPC protecting Johnson & Johnson’s
epilepsy drug topiramate entered into force was also published this week. This
SPC entered in to force on 25th September following the expiry of EP138441...
- A US application this week from IPCA claiming a formulation of paroxetine
hydrochloride adds to the Indian company’s limited patenting profile,
which boasts 3 PCT applications...
- Amgen patent protecting EPO revoked by House of Lords...
- A UK SPC application based on EP148605 was filed in 1993, however this
was withdrawn in 1996. A French CCP protecting the product...
- UK intial (“A0”) applications filed September 14th –
September 21st...
|
Week 42:
- This week sees the publication of a UK SPC application from Eli Lilly.
The application attempts to extend protection for atomoxetine...
- The formal announcement that an SPC protecting lomefloxacin has entered
into force was published in the PDJ this week. Hokuriku Pharmaceutical Co...
- Amendments which have been made to the specification of EP817864 under
Section 27 of the UK Patents Act 1977 were advertised for opposition purposes
on 13 October. The application to amend the specification...
- Merck & Co are currently working on a research project of small
molecule VEGFR-2 (Kdr) kinase inhibitors, for the treatment of cancer and other
angiogenic disorders. In June of this year it was reported at the 29th National
Symposium...
- Novartis has filed six applications this week on combinations of their
launched, ascomycin macrolactam derivative Elidel (pimecrolimus) with a wide
range of compounds. Two previous combination cases indicate that Novartis...
- UK intial (“A0”) applications filed September 7th –
September 14th...
|
Week 41:
- From this week’s UK Patents and Designs Journal (PDJ) we learn
that Syria acceded to the WIPO Convention in August 2004. More importantly perhaps...
- Also in the PDJ we are reminded of the grant of a Supplementary Protection
Certificate (SPC) to Rovi for bemiparin, as reported last week. In addition,
Wisconsin Alumni Research Foundation...
- The September issue of the Japanese Patent Gazette gave details of
extensions relating to three patents. Following the January 2004 launch in Japan
as Prodif, Pfizer...
- Berlex Labortaories, who as part of Schering are licensees for Cetus
Corp’s (now Chiron) interferon beta-1b product, received a 5 year extension...
- UK initial applications filed August 31st – September 1st 2004...
|
Week 40:
- Bemiparin, the low molecular weight heparin (LMWH) product from Laboratorios
Farmaceuticos Rovi SA, has been granted a UK Supplementary Protection Certificate
(SPC), as reported in this week’s UK Patents and Designs Journal...
- This week's PDJ also noted that the Yissum R&D Company of the Hebrew
University of Jerusalem had lodged an appeal against the rejection...
- The SPC had been rejected with the examiner citing earlier authorisations
for calcitriol. Yissum proposed that the earlier authorisations...
- Further SPC applications were published from Genzyme Corporation and
Schering AG. Genzyme applied for an SPC on colesevelam hydrochloride...
- The application from Schering covers the combination of estradiol and
drospirenone, also called Yasmin in the Orange Book...
- UK Initial (“A0”) Applications...
|
Week 39:
- The UK Patent & Designs Journal (PDJ) published on the Autumnal
Equinox includes a notice to the effect that the Patents Act 2004 came into
force that same day. Although that sounds like an important event for those
involved in patenting...
- Also in the PDJ, entry into force of a Supplementary Protection Certificate
(SPC) for troglitazone on August 30th 2004 is noted. This has the effect of
extending...
- A UK SPC application from Novartis was also published. The application
covering mycophenolate monosodium salt is based upon EP892640...
- UK initial applications filed August 18th – 23rd 2004...
|
Week 38:
- The August Gazette from Japan contained details of a number of patent
extension events. Two applications for 5 year extensions were reported for Eli
Lilly’s Evista...
- Pliva Pharmaceuticals had 3 applications which were granted five year
extensions to their product patent for azithromycin and its use in treatment
of a number of infections. Takeda gained...
- AstraZeneca obtained almost 4 years extension for one of their goserelin
patents whilst Sepracor...
- Four applications, three to Otsuka Pharmaceuticals and one to Taiho
Pharmaceuticals, were granted on TS-1 capsules...
- Other Japanese companies that were granted extensions were Eisai and
Santen Phramaceuticals with extensions of 3 and 4 years on 2 patents covering
bunazosin hydrochloride...
- UK Initial (“A0”) Applications...
|
Week 37:
- UK SPC applications filed by Columbia Labs and Yamanouchi...
- Xechem and University of Texas dispute ends...
- This week ExonHit has disclosed labcodes for several compounds, the
piperazine derivatives...
- Roche revives uPAR antagonist programme...
- UK Initial (“A0”) Applications...
|
Week 36:
- In this week’s Patents & Designs Journal (PDJ) from the
UK Patent Office, entry into force on August 10th 2004 is reported for the Novartis
antiviral penciclovir...
- Pfizer attracts attention this week with rather unusual claims to a
method of treating hypertension. The focus is on Kiss-1 antagonists...
- Ajinomoto provides technology relating to integrin alpha-4 inhibitors...
- Chiesi discloses beta amyloid inhibitors...
- UK Initial (“A0”) Applications...
|
Week 35:
- Prejay patent used for five UK SPCs...
- Novartis discloses new indications for the discontinued licarbazepine...
- This week CareX has published three PCTs relating to LXR (Liver X Receptor)
agonists. The company announced in March this year that an LXR modulator...
- GSK received a ruling this week from the United States District Court
in Wilmington, Delaware. The case involved use cases for GSK’s ondansetron...
- UK Initial (“A0”) Applications...
|
Week 34:
- The grant of Supplementary Protection Certificates (SPCs) for Shionogi’s
rosuvastatin and Novartis’ lumiracoxib is formally reported...
- This week, Altana Pharma AG filed for a UK SPC on ciclesonide, which
gained UK approval in April 2004 for the treatment of asthma in adults...
- GSK drops rosiglitazone countersuit...
- This week AstraZeneca has two cases describing stable dispersions of
solid, sub-micron particles in an aqueous medium. The medium contains an inhibitor
that prevents particles growth...
- Wisconsin gains European patent for QRX-101...
- UK initial (“A0”) applications due to be published at the
beginning of January 2005...
|
Week 33:
- Two PCT applications published this week, from two different
teams in California, seem to overlap...
- Teva has this week continued its interest in the diabetes treatment
nateglinide...
- Vitrolife the Swedish company focusing on transplant and fertility
systems, this week announced the patent approval...
- Bristol Myers Squibb is facing opposition to its Atherosclerosis,
Cerebrovascular ischemia and Myocardial...
- Medimmune has filed two cases relating to Vitaxin. The PCTs
describe a liquid formulation and a method of using the drug to
treat various diseases...
- GSK finds new use for NK1 antagonists...
- UK Initial ("A0") Applications filed July 5th - 12th 2004...
|
Week 32:
- Only two SPC events were reported in this weeks UK PDJ, the
grant of Health Research Inc's SPC for recombinant canarypox viruses
and vaccines...
- Several patent extensions were reported in the Japanese Gazette
for July, of which five were for Agrochemicals...
- Sumitomo Pharmaceuticals gained around 3.5 years extension for
one of their Japanese meropenem trihydrate...
- Daiichi Suntory Pharma received extensions of more than 3 years
to two patents for faropenem sodium, including the product patent...
- Aventis patent application for enoxaparin rejected again...
- This week saw the publication of research lead by Dr Friedrich
Grimminger of the University of Geissen. This research involved...
- Published this week is a case from Aventis disclosing the use
of their launched recombinant human insulin analog Lantus...
- Gilead has two cases published this week, one of which claims
a combination of tenofovir disoproxil fumarate and emtricitabine...
- UK Initial ("A0") Applications filed June 28th - July 5th 2004...
|
Week 31:
- The expiry of the UK SPC covering Chiron's anticancer recombinant
interleukin-2 compound aldesleukin...
- Chinese companies have this week announced they intend to challenge
the local patent for GSK's antidiabetic compound rosiglitazone...
- Ortho appears to have a particular interest in the choline salt
of topiramate...
- GSK claim nasal pump sprays for glucorticoid agonist...
- Application was made earlier this year to amend EP667852 (Pfizer
Healthcare)...
- Cortex Pharmaceuticals in collaboration with the University
of California and Wake Forest University is seeking to gain protection
on the use of AMPA...
- Phase 2 Discovery appear to have added to their development
pipeline...
- 2-Deoxyglucose has been known as an anti-neoplastic agent for
a number of years with articles stretching back as far as 1952.
US company Threshold Pharmaceuticals...
- UK Initial ("A0") Applications filed June 21st - 28th 2004...
|
Week 30:
- This week a UK SPC application for Biogen's antibody treatment
for Non-Hodgkin lymphoma...
- Official notification of UK SPCs entering into force was also
published this week...
- The expiry of P&Us UK SPC covering ceftiofur was officially
announced this week...
- EP817864 claiming a diagnostic and therapeutic system for Crohn's
disease and ulcerative colitis was granted in June 2002...
- PCT applications from Aventis published this week and last characterize
particular forms (A and C) of an antibacterial agent...
- Arden Pharmaceuticals have this week published a PCT application
disclosing diaryl methylpiperazine compounds...
- Possible disclosure of EGS001 and FP1198...
- UK Initial ("A0") Applications filed June 14th - 21st 2004...
|
Week 29:
- Protein Design Labs have this week published a PCT application
claiming the use of the discontinued investigational compound
ALX-40-4C...
- No new SPCs were lodged at the UK PTO this week. However, SPC
GB03/017 was granted to Ortho-McNeil Pharmaceutical, Inc for the
norelgestromin / ethinylestradiol...
- Patent extensions from Japan...
|
Week 28:
- Novartis attempt to protect eplerenone with an SPC...
- A further UK SPC application was also published this week, this
joint application from both Chiron and Novo Nordisk...
- Another slightly unusual case saw Eli Lilly announcing the launch
of Straterra (atomoxetine HCl) for treatment of ADHD...
- UK Initial ("A0") Applications filed May 31st - June 7th 2004...
|
Week 27:
- Supplementary Protection Certificate (SPC) events reported by
the UK Patent Office this week include the grant of five years'
additional protection for adefovir dipivoxil...
- There seems to have been some confusion over the UK designation
of EP200421 which covers Novo Nordisk's recombinant coagulation
Factor V11a...
- There has been some activity on the file of Lundbeck's EP1227088
prior to the expiry of the opposition period. On the grant of
the European patent, covering the crystallization of R,S-citalopram...
- The use of harkoseride, a peptide orginating with the University
of Houston and currently in Phase II clinical trials, is claimed
for treating allodynia...
- UK Initial ("A0") Applications filed May 24th - 31st 2004...
|
Week 26:
- Lead compounds from BMS, GSK, Pfizer and Roche...
- Quebec-based ViroChem Pharma Inc makes its first foray into
the arena of international patenting the publication of its first
PCT applications claiming...
- This week sees two interesting applications, both using specified
food products to deliver therapy. One, filed in Japanese, comes
from the Ghen Corporation and their method for treating...
- UK Initial ("A0") Applications filed May 17th - 24th 2004...
|
Week 25:
- Almirall Prodesfarma was granted a UK Supplementary Protection
Certificate (SPC) on May 24th for its almotriptan migraine therapy...
- Cabinet Alice de Pastors has just issued SPC News 17, and again
we are very grateful to have this expert attorney's view of supplementary
protection in the EU...
- Shionogi is seeking protection for salts of one particular phospholipase
A2 inhibitor, the basic molecule of which is already claimed in...
- Workers at Ortho-McNeil's base in San Diego are working on histamine
H3 antagonists with a structure similar to that of Gliatech's
cipralisant...
- Generic drug companies also feature this week in Section B,
where claims to new uses and formulations of known active ingredients
are covered...
- UK Initial ("A0") Applications filed May 10th- 17th 2004...
|
Week 24:
- SPCs from Millenium (bortezomib) and Euro-Celtique (Hydromorphone
hydrochloride)...
- Australian Patent Office denies Pfizer...
- Islamic Republic of Pakistan enters Paris Convention...
- Japan Tobacco and Tularik claim diacylglcerol acyltransferase
(DGAT) inhibitors...
- First applications from ProSkelia SAS and Shenzhen Chipscreen
Biosciences...
- Peptech and Agenix merger off...
- UK Initial ("A0") Applications filed May 3rd - 10th 2004...
|
Week 23:
- Teva and Ciba Speciality Chemical join forces over atorvastatin...
- This week sees the publication of two Ranbaxy patent applications
disclosing combined formulations of biguanide, formulated in a
extended release form...
- SPC for Sumitomo's meropenem enters into force...
- UK Initial "A0" Applications filed April 26th - May 3rd 2004...
|
Week 22:
- PIUG Conference, Baltimore...
- Mercury Therapeutics, a Massachusetts based biopharmaceutical
company targeting dysfunctional signal transduction...
- Wyeth has a PCT that describes using a combination of gemtuzumab
ozogamicin and an anthracycline of purine nucleoside analog to
treat acute leukemia...
- Large-scale production of therapeutic antibodies from Abbott
Bioresearch...
|
Week 21:
- RIP EU Community Patent?...
- The EPO has granted EP637237 to NPS and Brigham & Women's Hospital
this week. The subject matter is calcimimetic...
- Cyclacel has published four PCTs disclosing the use of CYC-202
(roscovitine) in combination with mitoxantrone, cisplatin, docetaxel
and gemcitabine...
- This week sees a PCT publication from Egalet covering a controlled
release formulation of carvedilol...
- Fujisawa has a PCT published disclosing a combination of tacrolimus
or its derivatives with...
- XenoPort, Inc of Santa Clara, California has an application
published this week claiming prodrugs of Lilly's launched antitumor
agent gemcitabine...
- Wellspring Pharmaceuticals has a published US application this
week relating to water-soluble formulations of Sn-mesoporphyrin...
|
Week 20:
- Expiry of Merck & Co's UK SPC for lisinopril and hydrochlorothiazide...
- The UK SPC covering Glaxo's asthma treatment salmeterol entered
into force on 18th April following the expiry of GB2140800...
- A decision was issued on 14th May by the Australian Patent Office
regarding the opposition by Lek against SB's Australian patent
covering a pediatric formulation of amoxycillin/clavulanic acid...
- An application has been made in the UK under Section 28 of the
Patents Act 1977 to restore EP626858 entitled "Use of protease
inhibitors as antiviral agents"...
- Bionumerik has a a non-polyglutamylatable dihydrofolate reductase
inhibitor MDAM currently in Phase I for cancer treatment...
- An application from the University of California this week continues
the work of Heike Wulff and her team in the systhesis and use
of triarylmethane (TRAM)...
- Pfizer and Poly-Med Inc have collaborated on two PCTs published
this week. They disclose liquid phase conjugates of ziprasidone...
|
Week 19:
- SPCs for quinapril hydrochloride and vinorelbine expire...
- Glaxo's failure to market zanamivir sufficiently is the subject
of litigation filed by Australian biotech company, Biota. The
nasally administered viral replication inhibitor...
- First IP filing for Chong Kun Dang's anticancer telomerase inhibitors...
- Telmisartan prodict patent specification amended...
- Zentiva Hlohovec has first application published...
- Three applications have been filed this week from Pizer relating
their atypical antipsychotic ziprasidone, used for the treatment
of schizophrenia...
- More university filings in relation to imatinib...
- UK Initial "A0" Applications filed March 30th - April 6th 2004...
|
Week 18:
- Breaking news as we went to press last week was the potentially
very important merger between Aventis and Sanofi-Synthelabo...
- SPC filed for AstraZeneca's fulvestrant. Genetech's trastuzumab
and Emory's emtricitabine...
- The content of an AstraZeneca PCT application this week points
towards the identity of its lead atrial repolarization delaying
agent, AZD-7009...
- Oxford Glycosciences and Bayer's Japanese research company working
together on anti-asthma compounds...
- UK Initial "A0" Applications filed March 23rd - 30th 2004...
|
Week 17:
- SPC application from Orion for Stalevo combination...
- Bayer increases activity surrounding nitrile analog of moxifloxacin...
- In the last few years, Bristol Myers Squibb has been investigating
a series of inosine monophosphate dehydrogenase (IMPDH) inhibitors,
based on VX-497...
- AstraZeneca's legal whirlwind surrounding budesonide/formoterol
combination...
- E Merck has two applications published this week relating to
antibodies that bind to ErbB1 receptors present on cancer tissues.
The first relates to a combination of the antibodies EMD-55900...
- Novartis, who has recently filed a number new use and combination
cases for the anti-cancer drug Imatinib...
- The biotechnology company Kosan Biosciences filed two applications
that were published this week relating to the microtubule inhibitor
epothilone D...
- AstraZeneca have three combination cases published this week,
two involving their Phase II anti-cancer compounds, ZD6474 and
ZD6126...
- UK Initial "A0" Applications filed March 9th - 22nd 2004...
|
Week 16:
- Thomson Corporation acquires Newport Strategies...
- Generic drug companies and API manufacturers with applications
published this week include firms from India, Italy, Spain, Korea
and Poland...
- Potentially more contentious is the application from Dr Reddy's
Laboratories, in which a crystalline form of amlodipine maleate
is claimed in terms of its X-ray diffraction parameters...
- The Spanish company Ragactives targets the antihistamine mizolastine,
while a tibolone process is claimed by Polish company Anpharm...
- The disclosure that Dr Reddy's has opened a Drug Master File
for quetiapine, the active ingredient of AstraZeneca's anti-schizophrenic
Seroquel...
|
Week 15:
- Yamanouchi consolidates platelet synthesis stimulant protection...
- UK Initial "A0" Applications filed March 3rd - 9th 2004...
|
Week 14:
- SPCs: Moxifloxacin granted, gemcitabine in force and amlodipine
expires...
- Two UK SPC applications were also published this week. The first
is from Yeda R&D and covers...
- Two cases relating to imatinib have appeared this week, each
assigned to an American university. Imatinib was developed by
Novartis...
- The resource being put by Merck & Co into PDE 4 inhibitors may,
on the evidence of patent filing, have yielded a lead compound.
Of the 76 specific compounds...
- Contrary to a disclosure in Bioorganic & Medicinal Chemistry
Letters in 2001, GlaxoSmithKline's interest in PPAR...
- UK Initial "A0" Applications filed February 23rd - 30th 2004...
|
Week 13:
- SPC in force for esomeprasole and applications for estradiol/trimegestone,
isopropyl unoprostone...
- An application this week from the Medical University of South
Carolina (MUSC) on methods and kits for testing drug susceptibility
of HIV features one American inventor...
- Aventis win appeal against refusal of EP grant...
- Talampanel applications granted for Lilly...
- UK Initial "A0" Applications filed February 16th - 23rd 2004...
|
Week 12:
- Extended protection for Mononine...
- Kissei protects lead dysuria drug...
- Enzyme-catalyzed chemistry from Rome...
- More anticholinergenic claims from Boehringer...
- UK Initial "A0" Applications filed February 10th - 16th 2004
2004...
|
Week 11:
- International Patent Information Conference and Exposition 2004...
- Extended protection for monoclonal antibody...
- Pfizer turns green...
- UK Initial "A0" Applications filed February 3rd - 10th 2004...
|
Week 10:
- Japanese patent extensions...
- Pfizer has a European patent granted this week. The subject
matter is a process to CP-118954, an acetyl cholinesterase (ACE)
inhibitor...
- This week sees the publication of two patent applications from
the University of Connecticut relating to novel biphenyl, biphenyl-like
and tricyclic cannabinoids...
- UK Initial "A0" Applications filed January 27th - February 3rd
2003...
|
Week 09:
- This week sees the expiry of Eli Lilly's UK SPC covering its
Parkinson's treatment pergolide...
- The UK SPC covering cefprozil, a Bristol-Myers Squibb antibiotic,
came into force on 27th January after the expiry of GB2135305...
- A team at Eisai's London-based laboratories within University
College is researching Jun N terminal kinase inhibitors...
- A more mysterious final product is that of which the Chengdu
List Pharmaceutical Company has made salts...
- A number of new processes to marketed drugs or their intermediates/physical
forms are covered by companies in India (Natco - citalopram, tamsulosin),
Korea...
- Generx has two applications relating to micellar formulations
of large-molecule drugs for administration through the buccal
region of the mouth...
- Vaccine Research International PLC has filed a UK initial application
(A0) for a safe vaccine to prevent bacterial infections. The company
is developing a vaccine...
- UK Initial "A0" Applications filed January 20th - 27th 2003...
|
Week 08:
- Bristol Myers Squibb's UK SPC for cefprozil entered into force
on 27th January...
- Warner-Lambert attracts attention this week with a block of
22 closely linked PCT applications relating to novel inhibitors
of the collagenase...
- Ranbaxy, at one time seen as primarily a generic drug manufacturer,
now has claims to novel M3 muscarinic receptor antagonists...
- This week sees another of WIPO's occasional specification mix-ups
with the inside pages of WO2004014361 (Glaxo, claiming antibacterial
aminocyclohexene quinolines) and...
- A new biotech start-up company, AngioDesign Inc, is likely to
license what appears to be its core screening technology disclosed...
- It would appear from this week's patent evidence, that Pfizer
has identified CP-481715 as the lead compound in its development
program for CCR1 antagonists...
- Boehringer Ingelheim is continuing to disclose uses and formulations
of its p38 MAP kinase inhibitor doramapimod...
- UK Initial "A0" Applications filed January 13th - 20th 2003...
|
Week 07:
- The announcement of the grant of a UK SPC to Novartis covering
its atopic dermatitis treatment, pimecrolimus...
- An SPC granted to Pharmacia & Upjohn, also receiving a five
year protection period, came into force this week following the
expiry of EP121036...
- Cancer Research UK and Duke University have been granted a Europe-wide
patent on BRCA2 gene sequences...
- Generic companies are not especially prominent in this week's
new publications, though Teva is an exception, with PCT applications
relating to gatifloxacin, clopidogrel and aztreonam...
- This week saw the publication of Wackvom Ltd's sixth PCT. All
of the company's applications relate to therapies...
- UK Initial "A0" Applications filed January 6th - 13th 2003...
|
Week 06:
- This week sees the formal announcement of the UK SPC expiries
for ramipril and reboxetine...
- Pfizer compounds appear to be the key targets of generics companies
this week, with applications from Chemagis...
- Other generic activity this week is limited to two applications
from Teva...
- This week, Sepracor has disclosed the use of a series of known
cyclooxygenase 2 (COX 2) inhibitors...
- Lundbeck announced on February 6th 2004, that it has settled
patent infringement cases against Ratiopharm and Destin Pharma...
- This week saw the publication of the first PCT to arise from
Hawaii Biotech's ROS (reactive oxygen species) program...
- Albachem Ltd, a small, privately owned custom peptide synthesis
company based in Scotland, has filed its first patent applications
with the help of pharmaceutical giant Amersham Biosciences...
- UK Initial "A0" Applications filed December 19th - 24th 2003...
|
Week 05:
- Three Supplementary Protection Certificate (SPC) expiries were
the only SPC events reported in the UK Patents and Designs Journal...
- Indian and Israeli manufacturers are among the companies claiming
process enhancements in this week's publications, but China, Japan,
Korea, Italy and Croatia...
- Tanabe Seiyaku Co Ltd seems to have no obvious reason for filing
initial applications in the UK, but on December 20th 2003 did
so as a means of initiating protection for novel compounds...
- Ultrasis plc, now claiming apparatus and systems for treating
epilepsy, specializes in computerized, drug-free solutions...
- Temrel Inc is a rarity, in the sense that it has filed a couple
of UK initial patent applications, but nothing else is known of
the enterprise, beyond...
- UK Initial "A0" Applications filed December 19th - 24th 2003...
|
Week 04:
- For the second consecutive week the UK Patent Office has no
Supplementary Protection Certificate (SPC) news to report. However,
from Japan...
- This week sees the announcement of a UK SPC application covering
Abbott's paricalcitol. This application is based on Wisconsin
Alumni Research Foundation's...
- AstraZeneca has a very tight cluster of four PCT applications
published this week, all filed on the same mid-July day in 2002,
and all naming a UK/US/Swedish inventor team...
- Indian contributors to the generic drugs scene published this
week include process development cases from Zydus-Cadila (pioglitazone),
Cipla (paclitaxel) and Alembic...
- In 2002 Unichem Laboratories Ltd, an Indian research company,
set up a joint venture in the UK with the erstwhile directors
of Bioglan Generics...
- UK Initial "A0" Applications filed December 16th - 23rd 2003...
|
Week 03:
- No Supplementary Protection Certificate (SPC) happenings are
reported in this week's Patents & Designs Journal...
- CLS Laboratories Inc of Daejeon-city in Korea, has virtually
no international patent property to date, and very little is know
of the company...
- The drug delivery technology covered in Section E (devices)
includes implants from Debiopharm, Polyzenix, and (apparently)
Scimed Life Systems; electroporation from Inovio...
- Metered dose inhalation preparations and their dispensers feature
in initial UK patent applications from two different companies
this week. 3M Innovative Properties Co...
- UK Initial "A0" Applications filed December 8th - 15th 2003...
|
Week 02:
- The UK Patent Office's Patents & Designs Journal (PDJ) for January
7th 2004 includes notices of grant for two Supplementary Protection
Certificates...
- Nigerian companies are represented in the Gazette only infrequently,
but this week there is a chemical process case from Urah Resources
of Ayangba...
- From the generic drug sector there are two process cases from
Biocon India Ltd, both using solid-state batch-fed fermentation...
- We came across an invention which could have a profound effect
on the future of the drug industry...
- UK Initial "A0" Applications filed December 1st - 8th 2003...
|
Week 01:
- Ropinirole's "double SPC"...
- BrainsGate's new approach to CNS...
- Missing drug patent?...
- Nevirapine and its sequel...
- Generics overview...
- UK Initial "A0" Applications filed November 17th - 24th 2003...
|
